Is an 88-year-old man with atrial fibrillation, active hematuria, orthostatic hypotension, and intolerance to beta‑blockers a candidate for aspirin and apixaban (Eliquis)?

Active Hematuria is an Absolute Contraindication to Anticoagulation—This Patient Should NOT Receive Eliquis (Apixaban)

An 88-year-old man with active hematuria should not be started on apixaban (Eliquis) or any anticoagulant until the bleeding is fully investigated and resolved. The combination of aspirin and apixaban is also contraindicated, as this significantly increases bleeding risk without established benefit 1.

Critical Safety Concerns

Active Bleeding Excludes Anticoagulation

The FDA label for Eliquis explicitly states that patients with "current certain types of abnormal bleeding" should not take the medication 2. Active hematuria represents ongoing bleeding and is a contraindication to anticoagulation therapy. Starting anticoagulation in this setting risks:

• Worsening existing hemorrhage
• Inability to control bleeding once anticoagulation is initiated
• Potential for life-threatening blood loss
• Masking of serious underlying pathology (malignancy, urological disease)

Aspirin + Apixaban Combination is Not Recommended

The safety and efficacy of combining apixaban with antiplatelet agents like aspirin have not been established 1. This combination substantially increases major bleeding risk without proven additional stroke prevention benefit in atrial fibrillation. The 2012 AHA/ASA Science Advisory explicitly states this as Class IIb evidence (safety/efficacy not established) 1.

Clinical Algorithm for This Patient

Step 1: Address the Active Hematuria FIRST

• Urgent urological evaluation to identify bleeding source
• Rule out malignancy, stones, infection, or structural abnormalities
• Achieve complete hemostasis before considering any antithrombotic therapy
• Monitor hemoglobin/hematocrit for stability

Step 2: Reassess Stroke Risk After Bleeding Resolved

At age 88 with atrial fibrillation, his CHA₂DS₂-VASc score is at minimum 2 points (age ≥75 = 2 points), likely higher with other comorbidities. This places him at high stroke risk requiring anticoagulation 3, 4, 5.

Step 3: Once Hematuria Resolved, Consider Apixaban Monotherapy

After complete resolution of hematuria, apixaban alone (not with aspirin) would be the appropriate choice 6, 4:

• Dose: Apixaban 5 mg twice daily is standard
• Dose reduction to 2.5 mg twice daily if he meets ≥2 of these criteria 4, 5:
  • Age ≥80 years (he's 88—meets this)
  • Weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL

Given his age of 88, if he also has low body weight OR renal impairment, the reduced dose of 2.5 mg twice daily would be appropriate 4, 5.

Step 4: Manage Orthostatic Hypotension Separately

His orthostatic hypotension and beta-blocker intolerance are relevant for rate control but don't contraindicate anticoagulation:

• Consider calcium channel blockers (diltiazem or verapamil) for rate control instead of beta-blockers 7
• Address volume status and medication review for orthostasis
• These issues should not delay appropriate stroke prevention once bleeding resolved

Why Apixaban Over Warfarin in This Patient

Apixaban offers significant advantages for an 88-year-old 6, 4, 8:

• 69% reduction in major bleeding vs warfarin (2.13% vs 3.09% per year) 6
• 50% reduction in intracranial hemorrhage 6, 9
• Superior efficacy in elderly patients: In the AVERROES trial subgroup analysis, patients ≥85 years had even greater relative benefit (HR 0.14 for stroke prevention) 8
• No dietary restrictions or INR monitoring required—important for elderly patients
• More predictable pharmacokinetics in advanced age

Common Pitfalls to Avoid

1. Never start anticoagulation with active bleeding—this is medical malpractice regardless of stroke risk
2. Don't combine aspirin with apixaban routinely—increases bleeding without proven benefit in AF 1
3. Don't use aspirin as a "safer" alternative—in the AVERROES trial, apixaban was superior to aspirin for stroke prevention with similar bleeding rates 10
4. Don't forget dose adjustment criteria—failure to reduce dose appropriately in elderly patients increases bleeding risk 4, 5
5. Don't assume orthostatic hypotension contraindicates anticoagulation—these are separate management issues

Summary Recommendation

Hold all antithrombotic therapy until hematuria is fully evaluated and resolved. Once bleeding is controlled and underlying cause addressed, initiate apixaban monotherapy with appropriate dose adjustment based on age, weight, and renal function. Aspirin should not be added to apixaban. His orthostatic hypotension requires separate management with non-beta-blocker rate control agents.